SETD2 and cancer: In the case of diabetes, which like cancer is characterized by a dysregulation of glucose metabolism, there are mixed results showing impaired (Catrina et al., 2004) or enhanced (Xiao et al., 2006; Isoe et al., 2010) HIF-1 pathway under high glucose conditions.